Abstract
The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Current Pharmaceutical Design
Title:Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Volume: 20 Issue: 14
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Abstract: The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990473
DOI https://dx.doi.org/10.2174/13816128113199990473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews Topical Clobetasol: An Overlooked Cause of Cushing Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Introduction from the Guest Editor: The Many Facets of Heme Oxygenase
Current Neurovascular Research Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Preface: (Commentary on the Special Issue on the Impact of Myogenic Tone in Health and Disease)
Current Vascular Pharmacology Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Cardiotonic Steroids, Hypertension and Cardiovascular Disease
Current Hypertension Reviews Meet Our Editorial Board Member
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Wet Chemistry Approaches for Synthesis of Gold Nanospheres, Nanorods and Nanostars
Current Nanoscience Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Molecular Docking, In-Silico ADMET Study and Development of 1,6- Dihydropyrimidine Derivative as Protein Tyrosine Phosphatase Inhibitor: An Approach to Design and Develop Antidiabetic Agents
Current Computer-Aided Drug Design Multiple Pregnancies After ART and How to Minimize their Occurrence
Current Women`s Health Reviews